2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

11:00AM-12:30PM: Abstract Number: 2785

Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study

5T046 ACR Abstract: Plenary Session III (2785–2790)

11:00AM-12:30PM: Abstract Number: 2789

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study

5T046 ACR Abstract: Plenary Session III (2785–2790)

11:00AM-12:30PM: Abstract Number: 2786

Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus

5T046 ACR Abstract: Plenary Session III (2785–2790)

11:00AM-12:30PM: Abstract Number: 2790

Screening of Patients with Adult-Onset Idiopathic Polyarteritis Nodosa for Deficiency of Adenosine Deaminase 2

5T046 ACR Abstract: Plenary Session III (2785–2790)

11:00AM-12:30PM: Abstract Number: 2788

The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-Induction for Treatment of Severe ANCA-Associated Vasculitis

5T046 ACR Abstract: Plenary Session III (2785–2790)

2:30PM-4:00PM: Abstract Number: 2803

48-Year Trends in Systemic Sclerosis Mortality in the United States, 1968-2015: Steady Decrease for 15 Years after 33 Years of Continuous Increase

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

2:30PM-4:00PM: Abstract Number: 2845

A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2844

A Mixed-Methods Feasibility Study Exploring the Cultural Adaptation of Walk with Ease to the United Kingdom

5T099 ARHP Abstract: Clinical Aspects & Outcomes Research–ARHP II (2844–2849)

2:30PM-4:00PM: Abstract Number: 2801

A Novel B-Cell-Helper IL-21-Producing CD8+ T Cell Subset Involved in the Pathogenesis of Rheumatoid Arthritis

5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

2:30PM-4:00PM: Abstract Number: 2811

Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older

5T087 ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science (2808–2813)

2:30PM-4:00PM: Abstract Number: 2800

Adenosine 2a Receptor Signals Act to Limit Autoimmune Arthritis By Inhibiting Pathogenic Germinal Center T Follicular Helper (GC-Tfh) Cells

5T092 ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2797–2801)

2:30PM-4:00PM: Abstract Number: 2819

Alcohol Consumption and the Risk of Coronary Heart Disease and Mortality in Patients with Rheumatoid Arthritis

5T088 ACR Abstract: RA–DX, Manifestations, & Outcomes IV: CV Co-Morbidities (2814–2819)

2:30PM-4:00PM: Abstract Number: 2841

Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

2:30PM-4:00PM: Abstract Number: 2835

Association between Changes in Gene Signature Expression and Disease Activity in Systemic Lupus Erythematosus

5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)

2:30PM-4:00PM: Abstract Number: 2805

Association of Dietary Quality Scores and Incident SLE in the Nurses’ Health Studies

5T086 ACR Abstract: Epidemiology & Pub Health III: SLE & SSc, Big Data & Large Cohorts (2802–2807)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].